Enbrel
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Enbrel (etanercept; Amgen/Pfizer/Takeda) is a dimeric fusion protein consisting of the extracellular ligand binding portion of tumor necrosis factor (TNF) receptor linked to the Fc portion of human immunoglobulin G1. Enbrel binds specifically to circulating TNF and blocks its interaction with cell surface TNF receptors, thereby retarding inflammation in autoimmune diseases. It is produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system.
Enbrel is approved for use in several autoimmune indications, namely rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and axial spondyloarthritis.
TABLE OF CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Enbrel : Axial spondyloarthritis (axSpA)
21 Enbrel : Rheumatoid arthritis (RA)
34 Enbrel : Psoriatic arthritis (PsA)
48 Enbrel : Psoriasis
LIST OF FIGURES
12 Figure 1: Enbrel for axial spondyloarthritis – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Enbrel in axial spondyloarthritis
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Enbrel in axial spondyloarthritis
17 Figure 4: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
29 Figure 5: Enbrel for rheumatoid arthritis – SWOT analysis
30 Figure 6: Datamonitor Healthcare’s drug assessment summary of Enbrel in rheumatoid arthritis
31 Figure 7: Datamonitor Healthcare’s drug assessment summary of Enbrel in rheumatoid arthritis
43 Figure 8: Enbrel for psoriatic arthritis – SWOT analysis
44 Figure 9: Datamonitor Healthcare’s drug assessment summary of Enbrel for psoriatic arthritis
45 Figure 10: Datamonitor Healthcare’s drug assessment summary of Enbrel for psoriatic arthritis
55 Figure 11: Enbrel for psoriasis – SWOT analysis
56 Figure 12: Datamonitor Healthcare’s drug assessment summary of Enbrel in psoriasis
57 Figure 13: Datamonitor Healthcare’s drug assessment summary of Enbrel in psoriasis
LIST OF TABLES
7 Table 1: Enbrel drug profile
8 Table 2: Enbrel pivotal trial data in axial spondyloarthritis
11 Table 3: Enbrel late-phase trial data in axial spondyloarthritis
18 Table 4: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
22 Table 5: Enbrel drug profile
24 Table 6: Enbrel pivotal trial data in rheumatoid arthritis
27 Table 7: Enbrel late-phase trial data in rheumatoid arthritis
28 Table 8: Enbrel ongoing late-phase clinical trials in rheumatoid arthritis
35 Table 9: Enbrel drug profile
37 Table 10: Enbrel pivotal trial data in psoriatic arthritis
40 Table 11: Enbrel late-phase trial data in psoriatic arthritis
49 Table 12: Enbrel drug profile
51 Table 13: Enbrel pivotal trial data in adult psoriasis
53 Table 14: Enbrel trial data in pediatric psoriasis
54 Table 15: Other late-phase trial data for Enbrel in adult psoriasis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Simponi 
Sign up to the